The Antiviral Activity of a Small Molecule Drug Targeting the NSP1-Ribosome Complex Against Omicron, Especially in Elderly Patients

The study explores the antiviral potential of small molecule drugs targeting the NSP1-ribosome complex against the Omicron variant of SARS-CoV-2, focusing on elderly patients. Researchers evaluated 7,495 drugs, identifying 93 with promising docking scores, and highlighted Golvatinib and Gliquidone as promising candidates due to their strong binding energy and safety profiles. These drugs could offer new therapeutic options for COVID-19, particularly for high-risk groups like the elderly, suggesting a potential substitute for current treatments. Further clinical trials are necessary to confirm these findings.